Chronic Plaque Psoriasis
Conditions
Keywords
Plaque, psoriasis, inflammatory skin disease, skin condition, thickening, flaking, scaly patches, skin disease
Brief summary
Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
Interventions
DRUGAIN457
AIN457 was administered intravenously.
DRUGPlacebo
Matching placebo to AIN457 was administered intravenously.
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of plaque psoriasis for at least 6 months prior to screening. The patients must meet all of the following criterion: 1. Coverage of the body surface area (BSA) of 10% or more with plaques 2. A score of 3 or more on the IGA scale 3. A PASI score of at least 12 at baseline
Exclusion criteria
* Have forms of psoriasis other than the required plaque psoriasis * Women of childbearing potential * Recent use of investigational drugs or treatment with other biological therapies (wash-out periods required) * Previous treatment with this investigational drug * Subjects with active or history of clinically significant cardiac, kidney or liver abnormalities; Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores | Baseline, Week 12 | PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). |
| Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56 | This outcome measure shows the proportion of participants in each of the AIN457 treatment groups who were relapse free throughout the study up to and including week 56. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, end of study (EOS) (up to week 56) | PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). |
| Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, EOS (up to week 56) | PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). |
| Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, EOS (up to week 56) | The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe. |
Participant flow
Recruitment details
The planned enrollment was for 100 participants. However, one center was prematurely terminated and the data from this center could not be used for analysis. Therefore, additional participants were randomized to replace the 30 participants from the early terminated center. As a result, a total of 130 participants were enrolled.
Participants by arm
| Arm | Count |
|---|---|
| AIN457 3 mg/kg Participants randomized to this arm received AIN457 3 mg/kg on day 1, and then matching placebo on days 15 and 29. | 30 |
| AIN457 10 mg/kg Participants randomized to this arm received AIN457 10 mg/kg on day 1, and then matching placebo on days 15 and 29. | 29 |
| AIN457 10 mg/kg x3 Participants randomized to this arm received AIN457 3 mg/kg on days 1, 15 and 29. | 31 |
| Placebo Participants randomized to this arm received matching placebo to AIN457 on days 1, 15 and 29 | 10 |
| Total | 100 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 1 | 0 |
| Overall Study | Lost to Follow-up | 1 | 2 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 13 | 5 | 11 | 5 |
Baseline characteristics
| Characteristic | AIN457 3 mg/kg | AIN457 10 mg/kg | AIN457 10 mg/kg x3 | Placebo | Total |
|---|---|---|---|---|---|
| Age, Continuous | 45.7 Years STANDARD_DEVIATION 9.29 | 43.5 Years STANDARD_DEVIATION 11.75 | 43.4 Years STANDARD_DEVIATION 10.9 | 40.1 Years STANDARD_DEVIATION 14.89 | 43.8 Years STANDARD_DEVIATION 11.09 |
| Sex: Female, Male Female | 6 Participants | 7 Participants | 5 Participants | 2 Participants | 20 Participants |
| Sex: Female, Male Male | 24 Participants | 22 Participants | 26 Participants | 8 Participants | 80 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 15 / 30 | 22 / 29 | 19 / 31 | 3 / 10 |
| serious Total, serious adverse events | 2 / 30 | 3 / 29 | 2 / 31 | 0 / 10 |
Outcome results
Primary
Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: Baseline, Week 12
Population: Participants from the PD Analysis Set, who had both baseline and week 12 values, were included in the analysis. As such, the population for each treatment group is different from the PD population in the participant flow. The PD analysis set included participants who had at least one dose of study medication and had no protocol deviations.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AIN457 3 mg/kg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores | -12.46 scores on a scale | Standard Deviation 7.668 |
| AIN457 10 mg/kg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores | -13.35 scores on a scale | Standard Deviation 6.195 |
| AIN457 10 mg/kg x3 | Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores | -18.02 scores on a scale | Standard Deviation 6.792 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores | -4.18 scores on a scale | Standard Deviation 4.698 |
Primary
Percentage of Participants Who Had Not Relapsed at Any Time in the Trial
This outcome measure shows the proportion of participants in each of the AIN457 treatment groups who were relapse free throughout the study up to and including week 56.
Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56
Population: PD analysis set participants (AIN457 groups only), who had not yet relapsed were included in the analysis at each time point. As a result, the number of participants at risk for relapse may decrease as the number of weeks on study increases. The PD set included participants who had at least one dose of study medication and no protocol deviations.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 2 (n=30,25,28) | 100.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 16 (n=16,19,26) | 53.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 20 (n=15,17,26) | 50.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 40 (n=6,7,14) | 20.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 14 (n=20,20,27) | 66.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 24 (n=13,17,25) | 43.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 28 (n=11,12,24) | 36.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 32 (n=9,9,19) | 30.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 36 (n=7,9,17) | 23.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 44 (n=4,7,10) | 13.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 48 (n=3,6,8) | 10.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 52 (n=3,5,5) | 10.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 56 (n=2,4,5) | 12.5 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 1 (n=30,25,29) | 100.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 4 (n=30,25,27) | 100.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 6 (n=30,24,27) | 100.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 12 (n=23,22,27) | 76.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 8 (n=30,24,27) | 100.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 10 (n=28,22,27) | 93.3 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 28 (n=11,12,24) | 48.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 32 (n=9,9,19) | 36.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 4 (n=30,25,27) | 100.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 36 (n=7,9,17) | 36.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 40 (n=6,7,14) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 44 (n=4,7,10) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 12 (n=23,22,27) | 88.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 48 (n=3,6,8) | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 10 (n=28,22,27) | 88.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 52 (n=3,5,5) | 20.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 6 (n=30,24,27) | 96.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 56 (n=2,4,5) | 22.2 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 14 (n=20,20,27) | 80.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 1 (n=30,25,29) | 100.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 8 (n=30,24,27) | 96.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 16 (n=16,19,26) | 76.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 20 (n=15,17,26) | 68.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 2 (n=30,25,28) | 100.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 24 (n=13,17,25) | 68.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 20 (n=15,17,26) | 89.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 28 (n=11,12,24) | 82.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 10 (n=28,22,27) | 93.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 8 (n=30,24,27) | 93.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 32 (n=9,9,19) | 65.5 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 12 (n=23,22,27) | 93.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 24 (n=13,17,25) | 86.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 14 (n=20,20,27) | 93.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 40 (n=6,7,14) | 48.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 4 (n=30,25,27) | 93.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 6 (n=30,24,27) | 93.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 44 (n=4,7,10) | 34.5 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 16 (n=16,19,26) | 89.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 2 (n=30,25,28) | 96.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 48 (n=3,6,8) | 27.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 36 (n=7,9,17) | 58.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 1 (n=30,25,29) | 100.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 52 (n=3,5,5) | 17.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants Who Had Not Relapsed at Any Time in the Trial | Week 56 (n=2,4,5) | 27.8 Percentage of participants |
Secondary
Percentage of Participants in Each Investigator Global Assessment (IGA) Category
The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe.
Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, EOS (up to week 56)
Population: PD analysis set participants, who had values at each week category, were included in the analysis. As such, the population at each week varies from the PD population in the participant flow. The PD analysis set included participants who had at least one dose of study medication and had no major protocol deviations.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Mild disease (n=11,12,23,2) | 20.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Very severe disease (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Almost clear (n=11,12,23,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Clear (n=22,22,26,4) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Clear (n=30,25,27,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Mild disease (n=12,8,13,5) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Almost clear (n=22,22,26,4) | 16.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Mild disease (n=30,24,27,7) | 50.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Almost clear (n=30,25,29,10) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Severe disease(n=30,25,27,9) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Mild disease (n=22,22,26,4) | 30.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Very severe disease (n=30,25,27,9) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Mild disease (n=3,7,11,1) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Clear (n=11,12,23,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Moderate disease (n=22,22,26,4) | 16.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Moderate disease (n=28,24,25,5) | 26.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8- Mild disease (n=30,24,27,7) | 40.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Clear (n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Almost clear (n=30,25,27,10) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Moderate disease (n=12,8,13,5) | 30.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Almost clear (n=30,24,27,7) | 23.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Almost clear(n=20,21,26,4) | 13.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Mild disease (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Almost clear (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Severe disease (n=14,17,24,2) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Mild disease(n=20,21,26,4) | 23.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Severe (n=22,22,26,4) | 10.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Moderate disease (n=30,24,27,7) | 26.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Mild disease (n=30,25,27,10) | 50.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Moderate disease (n=20,21,26,4) | 20.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Very severe disease (n=30,25,27,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Severe disease (n=20,21,26,4) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Almost clear (n=8,8,18,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Almost clear (n=30,24,27,7) | 33.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Severe disease(n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Almost clear (n=14,17,24,2) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Almost clear (n=9,9,19,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Almost clear (n=17,18,26,3) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Very severe disease(n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Clear (n=28,24,25,5) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Clear (n=14,17,24,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Mild disease (n=17,18,26,3) | 33.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Mild disease (n=3,7,10,0) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Moderate disease (n=30,25,27,10) | 46.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Clear (n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Moderate disease (n=17,18,26,3) | 10.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Very severe disease(n=15,18,26,3) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Severe disease (n=17,18,26,3) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Mild disease (n=30,25,29,10) | 23.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Very severe disease (n=12,8,13,5) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Severe disease(n=15,18,26,3) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Very severe disease (n=17,18,26,3) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Severe disease (n=30,25,27,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Moderate disease(n=30,24,27,7) | 26.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Almost clear (n=15,18,26,3) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Very severe (n=30,25,29,10) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Severe disease (n=6,8,14,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Severe disease (n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Almost clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Mild disease (n=14,17,24,2) | 23.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Moderate disease (n=14,17,24,2) | 16.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Very severe disease (n=11,12,23,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Severe disease (n=30,25,29,10) | 36.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Very severe disease (n=14,17,24,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Almost clear (n=28,24,25,5) | 30.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Mild disease (n=9,9,19,2) | 16.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Moderate disease(n=15,18,26,3) | 10.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Moderate disease (n=9,9,19,2) | 13.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Very severe disease (n=8,8,18,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Mild disease(n=15,18,26,3) | 30.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Mild disease (n=8,8,18,2) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Very severe disease (n=27,23,27,5) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Mild disease (n=6,8,14,2) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Mild disease (n=28,24,25,5) | 36.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Clear (n=8,8,18,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Clear (n=9,9,19,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Mild disease (n=27,23,27,5) | 33.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Moderate disease (n=3,7,10,0) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Severe disease (n=9,9,19,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Clear (n=6,8,14,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Clear (n=15,18,26,3) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Almost clear (n=6,8,14,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Very severe disease (n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Severe disease (n=8,8,18,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Severe disease (n=11,12,23,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Severe disease (n=28,24,25,5) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Clear (n=30,25,27,9) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Very severe disease (n=6,8,14,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Almost clear (n=12,8,13,5) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Almost clear (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Moderate disease (n=30,25,27,9) | 36.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Clear (n=17,18,26,3) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Moderate disease (n=3,7,11,1) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Very severe disease (n=28,24,25,5) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Moderate disease (n=30,25,29,10) | 66.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Severe disease (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Almost clear (n=30,25,27,9) | 16.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Very severe disease (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Moderate disease (n=30,25,29,10) | 60.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Severe disease (n=30,25,29,10) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Very severe disease (n=20,21,26,4) | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Clear (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Moderate disease (n=11,12,23,2) | 16.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Clear (n=27,23,27,5) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12- Moderate disease (n=27,23,27,5) | 16.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Moderate disease (n=6,8,14,2) | 13.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Severe disease (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Moderate disease (n=8,8,18,2) | 20.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Almost clear (n=27,23,27,5) | 26.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Very severe disease (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Severe disease (n=27,23,27,5) | 13.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Clear (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Clear (n=20,21,26,4) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Clear (n=12,8,13,5) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Mild disease (n=30,25,27,9) | 46.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Very severe disease (n=9,9,19,2) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Very severe (n=22,22,26,4) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Severe disease (n=12,8,13,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Moderate disease (n=20,21,26,4) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Severe (n=22,22,26,4) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Moderate disease (n=30,25,27,10) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Almost clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Severe disease (n=9,9,19,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Very severe disease (n=27,23,27,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Mild disease (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Moderate disease (n=30,25,29,10) | 68.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Clear (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12- Moderate disease (n=27,23,27,5) | 20.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Very severe (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Almost clear (n=30,25,29,10) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Clear (n=6,8,14,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Mild disease (n=27,23,27,5) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Mild disease (n=30,25,29,10) | 32.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Moderate disease (n=9,9,19,2) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Moderate disease (n=30,25,29,10) | 56.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Almost clear (n=27,23,27,5) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Mild disease (n=9,9,19,2) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Clear (n=30,25,27,10) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Almost clear (n=30,25,27,10) | 20.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Clear (n=28,24,25,5) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Very severe disease (n=30,25,27,9) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Almost clear (n=3,7,10,0) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Severe disease (n=30,25,27,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Very severe disease (n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Very severe disease (n=30,25,27,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Very severe disease (n=6,8,14,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Clear (n=30,25,27,9) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Almost clear (n=30,25,27,9) | 32.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Almost clear (n=9,9,19,2) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Severe disease (n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Mild disease (n=30,25,27,9) | 44.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Moderate disease (n=30,25,27,9) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Severe disease(n=30,25,27,9) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8- Mild disease (n=30,24,27,7) | 20.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Mild disease (n=30,24,27,7) | 32.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Clear (n=30,24,27,7) | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Almost clear (n=30,24,27,7) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Severe disease(n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Almost clear (n=30,24,27,7) | 32.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Moderate disease (n=30,24,27,7) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Very severe disease (n=8,8,18,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Very severe disease(n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Very severe disease (n=11,12,23,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Clear (n=30,24,27,7) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Mild disease (n=3,7,10,0) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Moderate disease(n=30,24,27,7) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Almost clear (n=28,24,25,5) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Clear (n=9,9,19,2) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Mild disease (n=28,24,25,5) | 20.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Severe disease (n=11,12,23,2) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Moderate disease (n=28,24,25,5) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Severe disease (n=28,24,25,5) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Moderate disease (n=11,12,23,2) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Very severe disease (n=28,24,25,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Almost clear (n=12,8,13,5) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Clear (n=27,23,27,5) | 32.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Mild disease (n=11,12,23,2) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Severe disease (n=27,23,27,5) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Almost clear (n=11,12,23,2) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Clear (n=22,22,26,4) | 32.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Almost clear (n=22,22,26,4) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Mild disease (n=12,8,13,5) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Clear (n=11,12,23,2) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Mild disease (n=22,22,26,4) | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Moderate disease (n=22,22,26,4) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Almost clear (n=8,8,18,2) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Severe disease (n=14,17,24,2) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Very severe (n=22,22,26,4) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Clear (n=20,21,26,4) | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Almost clear(n=20,21,26,4) | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Moderate disease (n=12,8,13,5) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Mild disease(n=20,21,26,4) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Mild disease (n=3,7,11,1) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Mild disease (n=14,17,24,2) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Mild disease (n=30,25,27,10) | 64.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Almost clear (n=14,17,24,2) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Severe disease (n=12,8,13,5) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Clear (n=17,18,26,3) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Almost clear (n=17,18,26,3) | 32.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Moderate disease (n=6,8,14,2) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Mild disease (n=17,18,26,3) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Clear (n=8,8,18,2) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Very severe disease(n=15,18,26,3) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Severe disease (n=17,18,26,3) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Very severe disease (n=12,8,13,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Moderate disease(n=15,18,26,3) | 20.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Almost clear (n=15,18,26,3) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Severe disease(n=15,18,26,3) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Clear (n=14,17,24,2) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Moderate disease (n=14,17,24,2) | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Very severe disease (n=14,17,24,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Severe disease (n=30,25,29,10) | 32.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Mild disease(n=15,18,26,3) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Mild disease (n=8,8,18,2) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Moderate disease (n=8,8,18,2) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Severe disease (n=8,8,18,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Very severe disease (n=9,9,19,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Clear (n=15,18,26,3) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Almost clear (n=6,8,14,2) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Mild disease (n=6,8,14,2) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Severe disease (n=6,8,14,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Severe disease (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Very severe disease (n=17,18,26,3) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Moderate disease (n=17,18,26,3) | 20.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Almost clear (n=3,7,11,1) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Moderate disease (n=3,7,11,1) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Very severe disease (n=20,21,26,4) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Very severe disease (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Clear (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Moderate disease (n=3,7,10,0) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Severe disease (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Severe disease (n=20,21,26,4) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Severe disease (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Very severe disease (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Very severe disease (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Clear (n=12,8,13,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Severe disease (n=27,23,27,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Very severe disease (n=6,8,14,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Clear (n=3,7,11,1) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Almost clear (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Mild disease (n=3,7,11,1) | 17.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Severe disease (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Clear (n=3,7,10,0) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Almost clear (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Mild disease (n=3,7,10,0) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Almost clear (n=12,8,13,5) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Mild disease (n=12,8,13,5) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Moderate disease (n=12,8,13,5) | 27.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Severe disease (n=12,8,13,5) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Severe disease (n=30,25,29,10) | 41.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Very severe disease (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Clear (n=30,25,27,9) | 17.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Mild disease (n=30,25,27,9) | 24.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Severe disease(n=30,25,27,9) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Clear (n=30,24,27,7) | 31.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Almost clear (n=30,24,27,7) | 48.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Severe disease(n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Very severe disease(n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Clear (n=30,24,27,7) | 41.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Moderate disease(n=30,24,27,7) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Almost clear (n=28,24,25,5) | 31.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Mild disease (n=28,24,25,5) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Moderate disease (n=28,24,25,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Severe disease (n=28,24,25,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Very severe disease (n=28,24,25,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Clear (n=27,23,27,5) | 48.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12- Moderate disease (n=27,23,27,5) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Clear (n=22,22,26,4) | 58.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Almost clear (n=22,22,26,4) | 17.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Mild disease (n=22,22,26,4) | 10.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Severe (n=22,22,26,4) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Very severe (n=22,22,26,4) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Almost clear(n=20,21,26,4) | 20.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Mild disease(n=20,21,26,4) | 10.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Severe disease (n=20,21,26,4) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Very severe disease (n=20,21,26,4) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Almost clear (n=17,18,26,3) | 20.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Mild disease (n=17,18,26,3) | 20.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Severe disease (n=17,18,26,3) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Clear (n=15,18,26,3) | 37.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Almost clear (n=15,18,26,3) | 31.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Clear (n=14,17,24,2) | 13.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Moderate disease (n=14,17,24,2) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Very severe disease (n=14,17,24,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Mild disease (n=8,8,18,2) | 31.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Moderate disease (n=8,8,18,2) | 17.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Very severe disease (n=8,8,18,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Clear (n=6,8,14,2) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Severe disease (n=6,8,14,2) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Moderate disease (n=3,7,11,1) | 17.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Very severe disease (n=3,7,11,1) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Moderate disease (n=3,7,10,0) | 17.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Severe disease (n=3,7,10,0) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Very severe disease (n=3,7,10,0) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Clear (n=12,8,13,5) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Very severe disease (n=12,8,13,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Almost clear (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Mild disease (n=30,25,29,10) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Moderate disease (n=30,25,29,10) | 55.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Very severe (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Almost clear (n=30,25,29,10) | 13.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Mild disease (n=30,25,29,10) | 48.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Moderate disease (n=30,25,29,10) | 37.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Severe disease (n=30,25,29,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Clear (n=30,25,27,10) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Almost clear (n=30,25,27,10) | 24.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Mild disease (n=30,25,27,10) | 44.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Moderate disease (n=30,25,27,10) | 17.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Severe disease (n=30,25,27,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Very severe disease (n=30,25,27,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Almost clear (n=30,25,27,9) | 44.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Moderate disease (n=30,25,27,9) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Very severe disease (n=30,25,27,9) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Mild disease (n=30,24,27,7) | 10.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Moderate disease (n=30,24,27,7) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Almost clear (n=30,24,27,7) | 34.5 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8- Mild disease (n=30,24,27,7) | 13.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Severe disease (n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Very severe disease (n=30,24,27,7) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Clear (n=28,24,25,5) | 48.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Almost clear (n=27,23,27,5) | 27.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Mild disease (n=27,23,27,5) | 13.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Very severe disease (n=27,23,27,5) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Moderate disease (n=22,22,26,4) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Clear (n=20,21,26,4) | 55.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Moderate disease (n=20,21,26,4) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Clear (n=17,18,26,3) | 44.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Moderate disease (n=17,18,26,3) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Very severe disease (n=17,18,26,3) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Mild disease(n=15,18,26,3) | 10.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Moderate disease(n=15,18,26,3) | 10.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Severe disease(n=15,18,26,3) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Very severe disease(n=15,18,26,3) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Almost clear (n=14,17,24,2) | 24.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Mild disease (n=14,17,24,2) | 37.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Severe disease (n=14,17,24,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Clear (n=11,12,23,2) | 10.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Almost clear (n=11,12,23,2) | 24.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Mild disease (n=11,12,23,2) | 27.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Moderate disease (n=11,12,23,2) | 13.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Severe disease (n=11,12,23,2) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Very severe disease (n=11,12,23,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Clear (n=9,9,19,2) | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Almost clear (n=9,9,19,2) | 13.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Mild disease (n=9,9,19,2) | 20.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Moderate disease (n=9,9,19,2) | 20.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Severe disease (n=9,9,19,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Very severe disease (n=9,9,19,2) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Clear (n=8,8,18,2) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Almost clear (n=8,8,18,2) | 10.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Severe disease (n=8,8,18,2) | 0.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Almost clear (n=6,8,14,2) | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Mild disease (n=6,8,14,2) | 13.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Moderate disease (n=6,8,14,2) | 20.7 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Clear (n=30,25,29,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Very severe disease (n=12,8,13,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Clear (n=12,8,13,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Very severe (n=22,22,26,4) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Very severe disease (n=3,7,10,0) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Clear (n=30,25,27,9) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Clear (n=20,21,26,4) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Moderate disease (n=30,25,27,10) | 80.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Moderate disease (n=20,21,26,4) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Moderate disease (n=3,7,10,0) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Very severe disease (n=3,7,11,1) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Severe disease (n=3,7,11,1) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Mild disease (n=3,7,11,1) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Almost clear (n=3,7,11,1) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Clear (n=17,18,26,3) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Clear (n=3,7,11,1) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Severe disease (n=9,9,19,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Severe disease (n=6,8,14,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Very severe disease (n=30,25,29,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Very severe disease (n=17,18,26,3) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Clear (n=6,8,14,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Very severe disease (n=8,8,18,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Moderate disease (n=8,8,18,2) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Almost clear (n=8,8,18,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Very severe disease (n=9,9,19,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Very severe (n=30,25,29,10) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Mild disease(n=15,18,26,3) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Very severe disease (n=14,17,24,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Clear (n=15,18,26,3) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Almost clear (n=6,8,14,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Moderate disease(n=15,18,26,3) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Severe disease (n=17,18,26,3) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Severe disease (n=30,25,29,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Severe disease(n=15,18,26,3) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Moderate disease (n=17,18,26,3) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Mild disease (n=17,18,26,3) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Severe disease (n=12,8,13,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Very severe disease(n=15,18,26,3) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 20 - Almost clear (n=17,18,26,3) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Clear (n=14,17,24,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Very severe disease (n=20,21,26,4) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Severe disease (n=20,21,26,4) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 48 - Moderate disease (n=3,7,11,1) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Almost clear (n=14,17,24,2) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Mild disease(n=20,21,26,4) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Clear (n=8,8,18,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Mild disease (n=14,17,24,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Moderate disease (n=14,17,24,2) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 16 - Almost clear(n=20,21,26,4) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Severe (n=22,22,26,4) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Moderate disease (n=12,8,13,5) | 30.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 28 - Severe disease (n=14,17,24,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Mild disease (n=22,22,26,4) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Almost clear (n=22,22,26,4) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Mild disease (n=12,8,13,5) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Clear (n=11,12,23,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Clear (n=22,22,26,4) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Severe disease (n=27,23,27,5) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Very severe disease (n=6,8,14,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Almost clear (n=11,12,23,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Moderate disease (n=6,8,14,2) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12- Moderate disease (n=27,23,27,5) | 30.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Mild disease (n=8,8,18,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Mild disease (n=11,12,23,2) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Very severe disease (n=28,24,25,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Severe disease (n=28,24,25,5) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | End of study - Almost clear (n=12,8,13,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Moderate disease (n=11,12,23,2) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Moderate disease (n=28,24,25,5) | 40.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Mild disease (n=28,24,25,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Almost clear (n=28,24,25,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Severe disease (n=3,7,10,0) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Severe disease (n=11,12,23,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Very severe disease (n=30,24,27,7) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Very severe disease(n=30,24,27,7) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 44 - Mild disease (n=6,8,14,2) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 32 - Very severe disease (n=11,12,23,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 40 - Severe disease (n=8,8,18,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Clear (n=9,9,19,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Severe disease(n=30,24,27,7) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Almost clear (n=30,24,27,7) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Clear (n=30,24,27,7) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Moderate disease (n=30,24,27,7) | 60.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Mild disease (n=30,24,27,7) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Mild disease (n=3,7,10,0) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Almost clear (n=30,24,27,7) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Very severe disease (n=30,25,27,9) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Severe disease(n=30,25,27,9) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Almost clear (n=9,9,19,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8- Mild disease (n=30,24,27,7) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Moderate disease(n=30,24,27,7) | 60.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Almost clear (n=30,25,27,9) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 6 - Clear (n=30,24,27,7) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 8 - Severe disease (n=30,24,27,7) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Very severe disease (n=30,25,27,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Severe disease (n=30,25,27,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Moderate disease (n=30,25,27,9) | 40.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Mild disease (n=30,25,27,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Almost clear (n=30,25,27,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Almost clear (n=3,7,10,0) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 10 - Clear (n=28,24,25,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 2 - Clear (n=30,25,27,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 24 - Almost clear (n=15,18,26,3) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Clear (n=27,23,27,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Severe disease (n=30,25,29,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Moderate disease (n=30,25,29,10) | 70.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Mild disease (n=9,9,19,2) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Almost clear (n=27,23,27,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Mild disease (n=30,25,29,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Almost clear (n=30,25,29,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 4 - Mild disease (n=30,25,27,9) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Mild disease (n=27,23,27,5) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 1 - Clear (n=30,25,29,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Moderate disease (n=30,25,29,10) | 70.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Mild disease (n=30,25,29,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Baseline - Almost clear (n=30,25,29,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 52 - Clear (n=3,7,10,0) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 12 - Very severe disease (n=27,23,27,5) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 36 - Moderate disease (n=9,9,19,2) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants in Each Investigator Global Assessment (IGA) Category | Week 14 - Moderate disease (n=22,22,26,4) | 30.0 Percentage of participants |
Secondary
Percentage of Participants With at Least 50% Improvement From Baseline in PASI
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, end of study (EOS) (up to week 56)
Population: PD analysis set: The PD analysis set included participants who had at least one dose of study medication and had no major protocol deviations which could impact the PD analysis. At weeks 28, 36, 44 and 48, only 28 of the 29 participants in the AIN457 10mg/kg X3 group had values for analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 8 | 73.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 16 | 50.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 40 | 20.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 48 (n=30,25,28,10) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 52 | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 20 | 46.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 12 | 66.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | End of study (up to week 56) | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 24 | 40.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 36 (n=30,25,28,10) | 23.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 32 | 30.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 44 (n=30,25,28,10) | 13.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 28 (n=30,25,28,10) | 33.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 4 | 56.7 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 28 (n=30,25,28,10) | 48.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 40 | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 32 | 36.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 36 (n=30,25,28,10) | 36.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 8 | 80.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 4 | 84.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 12 | 79.2 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | End of study (up to week 56) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 48 (n=30,25,28,10) | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 16 | 68.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 44 (n=30,25,28,10) | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 20 | 68.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 24 | 68.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 52 | 20.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 28 (n=30,25,28,10) | 82.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 4 | 89.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 8 | 93.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 12 | 93.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 16 | 89.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 20 | 89.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 24 | 86.2 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 32 | 65.5 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 36 (n=30,25,28,10) | 51.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 40 | 48.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 44 (n=30,25,28,10) | 32.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 48 (n=30,25,28,10) | 28.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 52 | 20.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | End of study (up to week 56) | 31.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 24 | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 16 | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 52 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 44 (n=30,25,28,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 12 | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | End of study (up to week 56) | 20.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 48 (n=30,25,28,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 8 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 4 | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 36 (n=30,25,28,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 32 | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 28 (n=30,25,28,10) | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 20 | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 50% Improvement From Baseline in PASI | Week 40 | 10.0 Percentage of participants |
Secondary
Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, EOS (up to week 56)
Population: PD analysis set: The PD analysis set included participants who had at least one dose of study medication and had no major protocol deviations which could impact the PD analysis. At weeks 28, 36, 44 and 48, only 28 of the 29 participants in the AIN457 10mg/kg X3 group had values for analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 8 - PASI 90 | 6.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 8 - PASI 75 | 53.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 16 - PASI 75 | 30.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 40 - PASI 90 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 4 - PASI 75 | 30.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 52 - PASI 90 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 16 - PASI 90 | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 32 - PASI 75 | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 36 - PASI 90 (n=30,25,28,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 32 - PASI 90 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 20 - PASI 75 | 23.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | End of study (up to week 56) - PASI 90 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 44 - PASI 90 (n=30,25,28,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 48 - PASI 75 (n=30,25,28,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 20 - PASI 90 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 28 - PASI 90 (n=30,25,28,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | End of study (up to week 56) - PASI 75 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 12 - PASI 75 | 40.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 24 - PASI 75 | 20.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 48 - PASI 90 (n=30,25,28,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 4 - PASI 90 | 3.3 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 40 - PASI 75 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 24 - PASI 90 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 52 - PASI 75 | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 12 - PASI 90 | 10.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 44 - PASI 75 (n=30,25,28,10) | 0.0 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 28 - PASI 75 (n=30,25,28,10) | 16.7 Percentage of participants |
| AIN457 3 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 36 - PASI 75 (n=30,25,28,10) | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 16 - PASI 90 | 40.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 40 - PASI 90 | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 28 - PASI 90 (n=30,25,28,10) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 52 - PASI 90 | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 32 - PASI 75 | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 8 - PASI 75 | 72.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 40 - PASI 75 | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 32 - PASI 90 | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 36 - PASI 75 (n=30,25,28,10) | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 36 - PASI 90 (n=30,25,28,10) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 8 - PASI 90 | 44.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 52 - PASI 75 | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 12 - PASI 75 | 75.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | End of study (up to week 56) - PASI 75 | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 12 - PASI 90 | 54.2 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 16 - PASI 75 | 60.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 48 - PASI 90 (n=30,25,28,10) | 4.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | End of study (up to week 56) - PASI 90 | 0.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 4 - PASI 75 | 56.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 48 - PASI 75 (n=30,25,28,10) | 12.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 20 - PASI 75 | 52.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 20 - PASI 90 | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 44 - PASI 90 (n=30,25,28,10) | 8.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 24 - PASI 75 | 40.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 44 - PASI 75 (n=30,25,28,10) | 16.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 24 - PASI 90 | 24.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 4 - PASI 90 | 28.0 Percentage of participants |
| AIN457 10 mg/kg | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 28 - PASI 75 (n=30,25,28,10) | 36.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 48 - PASI 90 (n=30,25,28,10) | 3.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | End of study (up to week 56) - PASI 75 | 13.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 4 - PASI 75 | 65.5 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 4 - PASI 90 | 48.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 8 - PASI 75 | 89.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 8 - PASI 90 | 72.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 12 - PASI 75 | 82.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 12 - PASI 90 | 75.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 16 - PASI 75 | 82.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 16 - PASI 90 | 79.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 20 - PASI 75 | 82.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 20 - PASI 90 | 65.5 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 24 - PASI 75 | 69.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 24 - PASI 90 | 62.1 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 28 - PASI 75 (n=30,25,28,10) | 60.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 28 - PASI 90 (n=30,25,28,10) | 42.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 32 - PASI 75 | 44.8 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 32 - PASI 90 | 31.0 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 36 - PASI 75 (n=30,25,28,10) | 28.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 36 - PASI 90 (n=30,25,28,10) | 14.3 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 40 - PASI 75 | 21.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 40 - PASI 90 | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 44 - PASI 75 (n=30,25,28,10) | 10.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 44 - PASI 90 (n=30,25,28,10) | 3.6 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 48 - PASI 75 (n=30,25,28,10) | 10.7 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 52 - PASI 75 | 6.9 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 52 - PASI 90 | 3.4 Percentage of participants |
| AIN457 10 mg/kg x3 | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | End of study (up to week 56) - PASI 90 | 10.3 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 4 - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 40 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 24 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 24 - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 52 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 44 - PASI 75 (n=30,25,28,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 20 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | End of study (up to week 56) - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 44 - PASI 90 (n=30,25,28,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 20 - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 16 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 52 - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 16 - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 12 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 48 - PASI 90 (n=30,25,28,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 12 - PASI 75 | 10.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 8 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 48 - PASI 75 (n=30,25,28,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 8 - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 36 - PASI 75 (n=30,25,28,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 4 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 36 - PASI 90 (n=30,25,28,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 32 - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 32 - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | End of study (up to week 56) - PASI 90 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 40 - PASI 75 | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 28 - PASI 90 (n=30,25,28,10) | 0.0 Percentage of participants |
| Placebo | Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI | Week 28 - PASI 75 (n=30,25,28,10) | 0.0 Percentage of participants |